Converd Pharmaceutical
Latest round
- Series C
Last raised
- Aug 2022
Total raised
- Undisclosed
Investors
- 5
About Converd Pharmaceutical
Based in Hangzhou, China and founded in 2012, Converd Pharmaceutical operates as an innovative drug developer specializing in oncolytic viral drugs. The company has applied for 75 domestic and foreign patents. The company has built a research and development center of over 1000 square meters and built a cytology laboratory, and an SPF certified laboratory animal house. In 2017, the company was awarded the certificate of Hangzhou enterprise high-tech research and development center.,Ltd. The company's business is a new drug creation industry involving medicinal chemistry, biology, pharmaceutical engineering, immunology, and pharmacological toxicology. The company has 3 major novel oncolytic virus drug development platforms, including adenovirus, caccinia virus and herpes simplex virus.
Who invested in Converd Pharmaceutical
5 investors across 2 rounds
See all investors in Converd Pharmaceutical
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Converd Pharmaceutical
Who invested in Converd Pharmaceutical?
Converd Pharmaceutical has 5 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Converd Pharmaceutical raised?
Converd Pharmaceutical has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Converd Pharmaceutical last raise money?
Converd Pharmaceutical's most recent round on record is a Series C, in Aug 2022.
What does Converd Pharmaceutical do?
Based in Hangzhou, China and founded in 2012, Converd Pharmaceutical operates as an innovative drug developer specializing in oncolytic viral drugs.
Where is Converd Pharmaceutical headquartered?
Converd Pharmaceutical is headquartered in Hangzhou, China.
Which VCs invest in companies like Converd Pharmaceutical?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Converd Pharmaceutical's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Converd Pharmaceutical? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.